Oncology Clinical Trials Market to Expand at A CAGR of 4.7%by 2032
Synopsis of the Market:
The oncology
clinical trials market had a global valuation of USD 8.43 billion in 2022
and is projected to ascend to USD 12.75 billion by 2032, showcasing a compound
annual growth rate (CAGR) of 4.7% throughout the forecast period. This market
expansion is predominantly fueled by factors such as the escalating incidence
of cancer, heightened demand for personalized medicine, and the increasing
necessity for innovative and efficacious cancer therapies.
The escalating prevalence of cancer worldwide emerges as a
pivotal catalyst propelling the growth in revenue of the oncology clinical
trials market. According to the World Health Organization (WHO), cancer ranks
as the second leading cause of mortality globally, with approximately 9.6
million deaths recorded in 2018. The imperative for effective cancer treatments
is prompting a surge in oncology clinical trials, anticipated to bolster market
revenue growth.
Get a sample copy of the Oncology
Clinical Trials Market report: https://www.reportsanddata.com/download-free-sample/6315
Another significant driver of revenue growth in the oncology
clinical trials market is the burgeoning demand for personalized medicine.
Personalized medicine entails the development of treatments customized to an
individual's genetic makeup, potentially enhancing treatment efficacy while
minimizing adverse effects. Oncology clinical trials are instrumental in this
endeavor, facilitating the identification of genetic biomarkers for the
formulation of targeted therapies, consequently fostering market revenue
growth.
Moreover, the quest for novel and potent cancer treatments
contributes to the revenue surge in the oncology clinical trials market.
Conventional treatments like chemotherapy and radiation therapy, albeit
effective, entail considerable side effects, spurring the quest for alternative
therapies that offer superior efficacy with fewer adverse reactions. Oncology
clinical trials serve as pivotal platforms for evaluating the safety and
efficacy of innovative cancer treatments, including immunotherapy, gene
therapy, and targeted therapies, thereby fostering market revenue growth.
The adoption of digital technologies in oncology clinical
trials is also a pivotal factor driving market revenue growth. Technologies
such as Electronic Data Capture (EDC), Clinical Trial Management Systems
(CTMS), and electronic Patient-Reported Outcomes (ePRO) streamline the clinical
trial process, augmenting data accuracy, and consequently propelling market
revenue growth. Additionally, the escalating outsourcing of clinical trial
services by pharmaceutical and biotechnology companies augments market revenue
growth, enabling firms to concentrate on core competencies while curbing
in-house clinical trial management costs.
Nevertheless, market revenue growth faces constraints due to
the high costs associated with oncology clinical trials and the intricate
regulatory landscape. Conducting oncology clinical trials incurs substantial
expenses encompassing drug costs, patient recruitment and retention expenses,
and trial management expenditures. Furthermore, navigating the complex regulatory
terrain governing clinical trials poses challenges, particularly for
multi-country trials, constraining market revenue growth prospects.
Key Insights:
Phase IV trials are projected to witness rapid revenue growth
during the forecast period. Conducted subsequent to treatment approval by
regulatory authorities, phase IV trials evaluate long-term treatment safety and
efficacy in larger patient cohorts.
Trial Design Analysis: In terms of trial design, the global
oncology clinical trials market is segregated into interventional and
observational trials. Interventional trials are poised to capture the largest
revenue share during the forecast period, primarily driven by the
administration of novel treatments to assess safety and efficacy. The
escalating cancer prevalence and demand for innovative treatments underscore
the prominence of interventional trials. Additionally, advancements in
technology fostering targeted and immunotherapies accentuate the necessity for
interventional trials, further amplifying market growth.
Major Companies and Competitive Landscape: The global
oncology clinical trials market portrays high competitiveness, characterized by
numerous large and medium-sized players commanding a significant market share.
These players deploy various strategies such as mergers and acquisitions,
strategic agreements, and product innovation to consolidate their market
presence. Major companies in the market include Parexel International
Corporation, ICON plc, Pharmaceutical Product Development, LLC, PRA Health
Sciences, Inc., PPD, Inc., Syneos Health, Charles River Laboratories
International, Inc., Covance, Inc., Quest Diagnostics, PharPoint Research,
Inc., and Veristat, Inc.
Strategic Developments: Various strategic collaborations and
acquisitions signify the competitive landscape of the oncology clinical trials
market, aiming to accelerate clinical trial timelines, enhance patient
experience, and bolster oncology treatment development. For instance: In 2020,
Syneos Health and AstraZeneca collaborated to expedite clinical trial timelines
and enhance patient experience through innovative technology and operational
models. In 2021, ICON plc and Novartis joined forces to accelerate the
development of new cancer treatments leveraging digital technology and
real-world data analysis. In the same year, PRA Health Sciences, Inc. acquired
CareLex, a global scientific and regulatory affairs consulting firm, expanding
its regulatory expertise and bolstering oncology clinical trial offerings. Additionally,
in 2021, Pharmaceutical Product Development, LLC (PPD) announced the
acquisition of Science 37, a clinical research technology and services
provider, aiming to enhance its virtual trial capabilities and accelerate
oncology treatment development. Furthermore, in 2020, Parexel International
Corporation introduced 'The Connected Journey,' a decentralized clinical trial
platform facilitating patient participation from home, thereby minimizing
hospital visits.
Explore Trending Reports:
Pressure
Sensitive Adhesives Market-https://www.reportsanddata.com/report-detail/pressure-sensitive-adhesive-market
Construction
Adhesive Market-https://www.reportsanddata.com/report-detail/construction-adhesive-market
Basalt
Fiber Market-https://www.reportsanddata.com/report-detail/basalt-fiber-market
Ammonium
Nitrate Market-https://www.reportsanddata.com/report-detail/ammonium-nitrate-market
Roofing
Systems Market-https://www.reportsanddata.com/report-detail/roofing-systems-market
Polyimide
Films Market-https://www.reportsanddata.com/report-detail/polyimide-film-market
Plastic
Fasteners Market-https://www.reportsanddata.com/report-detail/plastic-fasteners-market
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/6315
Thank
you for reading our report. To know more about the customization or any query
about the report contents, please connect with us and our team will ensure the
report is tailored to meet your requirements.
About Reports and Data
Reports
and Data is a market research and consulting company that provides syndicated
research reports, customized research reports, and consulting services. Our
solutions purely focus on your purpose to locate, target, and analyse consumer
behaviour shifts across demographics, across industries, and help clients to
make smarter business decisions. We offer market intelligence studies ensuring
relevant and fact-based research across multiple industries, including Healthcare,
Touch Points, Chemicals, Products, and Energy. We consistently update our
research offerings to ensure our clients are aware of the latest trends
existent in the market. Reports and Data has a strong base of experienced
analysts from varied areas of expertise. Our industry experience and ability to
develop a concrete solution to any research problems provides our clients with
the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press
Release: https://www.reportsanddata.com/press-release
Comments
Post a Comment